Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Flouvat, B; Decourt, S; Aubert, P; Potaux, L; Domart, Marie-Charlotte; Goupil, A; Baglin, A

doi:10.1111/j.1365-2125.1980.tb01065.x

Cited by 40 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After haemodialysis, in patients undergoing regular dialysis treatment, the plasma half-life was slightly shorter than in patients with terminal renal failure but that have not yet been dialyzed (CLcr between 4 and 10 ml/min). We have also observed this phenomenon with atenolol, a drug in which the plasma half-life after dialysis (51.2 + 17.3 h) is shorter than that in patients before the first haemodialysis treatment (73.4 ± 28.8 h) (Flouvat et al, 1980). In our patients, the apparent tinidazole volume of distribution (0.64 ± 0.03 1/kg) was equivalent to extra and intracellular water volume (0.55-0.65 1/kg) (Rowland & Tozer, 1980).…”

Section: Discussionmentioning

confidence: 64%

Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Flouvat¹,

Imbert²,

Dubois³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

The pharmacokinetics of tinidazole after infusion (800 mg in 15 min) were studied in 12 patients with chronic renal failure (RI) and in five patients undergoing regular dialysis treatment (RD). Tinidazole elimination plasma half‐life was 15.09 +/‐ 0.68 h (mean +/‐ s.e. mean) (RI) and 12.9 +/‐ 1.0 h after dialysis (RD), but there was a significant decrease in half‐life during dialysis (4.25 +/‐ 0.43 h) P less than 0.001). The apparent volume of distribution (0.64 +/‐ 0.03 l/kg) was equal to extra and intracellular water volume and tinidazole was little bound to plasma protein (8%). There was a slight sex difference in apparent volume of distribution between male patients (0.70 +/‐ 0.09 l/kg) and female patients (0.59 +/‐ 0.10 l/kg) (P = 0.07), but as body clearance decreases in the same order, there was no modification of plasma half‐life. In renal failure, pharmacokinetics of tinidazole were not disturbed because no correlation between half‐life, body clearance and creatinine clearance occurred; urine elimination was about 7% of administered dose. Plasma clearance during dialysis was 49.9 +/‐ 3.2 ml/min and about 43% of the available drug was eliminated during the 6 h dialysis procedure. These results suggest that an additional half‐dose infusion should be given after the end of dialysis in patients undergoing regular dialysis treatment.

show abstract

Section: Discussionmentioning

confidence: 64%

Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Flouvat¹,

Imbert²,

Dubois³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The half-life of atenolol has been shown to be prolonged in patients with renal impairment and to correlate inversely with creatinine clearance (McAinsh et al, 1980). Previous studies have shown that patients having creatinine clearance less than 10 mlmin would be expected to have atenolol half-lives of between 35 and 100 h. In contrast in patients with chronic renal failure who undergo haemodialysis the elimination of atenolol during the period of dialysis is more rapid and the measured half-lives approximate to those observed in normal volunteers with normal renal function, suggesting that atenolol is cleared across the dialysis membrane (Flouvat et al, 1980). CAPD is increasingly used in the U.K. as therapy for chronic renal failure but the clearance of atenolol into the peritoneum has not been previously studied.…”

Section: Discussionmentioning

confidence: 92%

Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

Salahudeen

Wilkinson

McAinsh

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

The elimination of atenolol (20 mg i.v.) has been studied in seven patients with renal failure on continuous ambulatory peritoneal dialysis (CAPD). Although atenolol was eliminated in the peritoneal fluid, the amount recovered in 24 h was relatively low (1.2 +/‐ 0.15 mg). The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/‐ 0.058 l/h and 0.152 +/‐ 0.018 l/h respectively. This was considerably less than calculated total body clearance (1.21 +/‐ 0.086 l/h). The kinetics of atenolol in CAPD are worthy of further study.

show abstract

“…Massive continued absorption is possible, but unlikely based on removal of substantial pill fragments and declining concentrations. Plasma atenolol concentrations have also been observed to increase post-dialysis reflecting redistribution from the tissue in HD patients [8,21]. Tissue may therefore be a large reservoir, especially after overdose.…”

Section: Discussionmentioning

confidence: 95%

Massive Atenolol, Lisinopril, and Chlorthalidone Overdose Treated with Endoscopic Decontamination, Hemodialysis, Impella Percutaneous Left Ventricular Assist Device, and ECMO

et al. 2014

View full text Add to dashboard Cite

Background Overdose of cardiovascular medications is increasingly associated with morbidity and mortality. We present a case of substantial atenolol, chlorthalidone, and lisinopril overdose treated by multiple modalities with an excellent outcome. Conclusion Aggressive medical intervention did not provide sufficient hemodynamic stability in this patient with refractory cardiogenic and distributive shock. Impella® percutaneous left ventricular assist device and extracorporeal membrane oxygenation provided support while the effects of the overdose subsided. We present concentrations demonstrating removal of atenolol with continuous venovenous hemodiafiltration. This is the first report of esophagogastroduo denoscopy decontamination of this overdose with a large pill fragment burden.

show abstract

Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Cited by 40 publications

References 17 publications

Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

Massive Atenolol, Lisinopril, and Chlorthalidone Overdose Treated with Endoscopic Decontamination, Hemodialysis, Impella Percutaneous Left Ventricular Assist Device, and ECMO

Contact Info

Product

Resources

About